PSTI
NASDAQPluristem Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Latest news
25 items- PRIndependence Realty Trust Appoints Craig Macnab to its Board of DirectorsWaives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,
- SECPluristem Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- 13D/GSEC Form SC 13D filed by Pluristem Therapeutics Inc.SC 13D - Pluri Inc. (0001158780) (Subject)
- SECSEC Form D filed by Pluristem Therapeutics Inc.D - Pluri Inc. (0001158780) (Filer)
- SECPluristem Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- INSIDERSEC Form 4: Yanay Yaky was granted 334,821 shares, increasing direct ownership by 23% to 1,760,125 units4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERSEC Form 4: Aberman Zami sold $1,940 worth of shares (2,000 units at $0.97), decreasing direct ownership by 0.13% to 1,491,973 units4 - Pluri Inc. (0001158780) (Issuer)
- SECPluristem Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- SECSEC Form 10-Q filed by Pluristem Therapeutics Inc.10-Q - Pluri Inc. (0001158780) (Filer)
- SECPluristem Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Pluri Inc. (0001158780) (Filer)
- SECPluristem Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- SECSEC Form 424B5 filed by Pluristem Therapeutics Inc.424B5 - Pluri Inc. (0001158780) (Filer)
- SECSEC Form 10-K filed by Pluristem Therapeutics Inc.10-K - Pluri Inc. (0001158780) (Filer)
- SECPluristem Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- NEWSDaily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral PactHere's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pluristem Therapeutics Changes its Name To Pluri Pluristem Therapeutics Inc (NASDAQ:PSTI) will be renamed Pluri Inc and start trading on NASDAQ under the ticker PLUR from July 26. The change reflects a broader strategy of leveraging its 3D cell expansion technology to develop cell-based products that can be harnessed for various fields beyond medicine. AstraZeneca's Enhertu Under FDA Priority Review For HER2-Low Metastatic Breast Cancer The FDA has accepted AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSNKY) supplemental application seeking approval for Enhertu (trastuzumab derux
- PRPluri CEO Issues Shareholder UpdateHAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Pluri: One simple, short word of Greek origin that encapsulates the strategic evolution for our Company. This is our new name. Today, I am proud to share the vision of Pluri: to help pioneer a biotech revolution to create a range of next-generation cell-based products that improve human wellbeing, increase sustainability, and advance solutions to humanity's greatest challenges. In early 2021,
- PRPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesAs of July 26, 2022, Pluri's stock will trade under the symbol PLURThe new name reflects the Company's strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and sustainabilityVisit our new Company website: www.pluri-biotech.com HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company, today announced its name change (NASDAQ:PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harness
- NEWS12 Health Care Stocks Moving In Thursday's After-Market SessionGainers Hanger (NYSE:HNGR) stock moved upwards by 27.1% to $18.75 during Thursday's after-market session. The company's market cap stands at $731.7 million. Biophytis (NASDAQ:BPTS) stock rose 13.92% to $0.99. The company's market cap stands at $16.2 million. IsoPlexis (NASDAQ:ISO) shares rose 12.31% to $3.74. The company's market cap stands at $146.1 million. Delcath Systems (NASDAQ:DCTH) shares increased by 11.13% to $4.89. The company's market cap stands at $38.6 million. Plus Therapeutics (NASDAQ:PSTV) shares moved upwards by 10.0% to $0.55. The company's market cap stands at $12.2 million. The company's, Q2 earnings came out today. Vallon Pharmaceuticals (NASDAQ:VLON) stock increas
- NEWSAlliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4Alliance Global Partners analyst James Molloy maintains Pluristem Therapeutics (NASDAQ:PSTI) with a Buy and lowers the price target from $9.5 to $4.
- NEWSHC Wainwright Reiterates On Pluristem After Encouraging Initial DataYesterday Pluristem Therapeutics Inc (NASDAQ:PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery. HC wainwright believes the muscle strength results from the Phase 3 trial confirm the results seen in the Phase 1/2 trial, in which increases in gluteus medius strength and volume were observed at 26 weeks post-treatment. The analyst reiterates a Buy rating with a price target of $10. Related: Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery. "Given these data showing PLX-PAD's ability to improve muscle strength, the panelist believes that these cells have po
- NEWSPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture SurgeryPluristem Therapeutics Inc (NASDAQ:PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short Physical Performance Battery (SPPB) test at week 26. The SPPB is a series of physical performance tests used in older persons to assess lower extremity function and mobility. PLX-PAD was demonstrated to be an effective accelerator of muscle strength and regeneration. Related: Pluristem's PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients. A significant increase in Hip Abduction Streng
- SECPluristem Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - PLURISTEM THERAPEUTICS INC (0001158780) (Filer)
- NEWSUPDATE: Pluristem Reports Results From Its Phase III Study Did Not Meet The Primary Endpoint
- NEWSPluristem Reports Topline Results From Its Phase III Study Of Muscle Regeneration Following Hip Fracture SurgeryPluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) (“Pluristem” or the “Company”), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study. The Company designed the study to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for hip fracture. The study enrolled 240 patients in the United States, Europe, and Israel. PLX-PAD was demonstrated to be an effective accelerator of muscle strength and regeneration. A significant increase in Hip Abduction Strength (HAS) was observed at week 26 and week 5
- PRPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryThe Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, July 13, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) ("Pluristem" or the "Company"), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study. The Company designed the study to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of mu
PSTI FAQ
5 questionsWhat does Pluristem Therapeutics Inc. do?
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and...Where does PSTI stock trade?
Pluristem Therapeutics Inc. (PSTI) is listed on NASDAQ.What sector and industry is PSTI in?
Pluristem Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to PSTI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PSTI side-by-side with any of them on Quantisnow.How can I track PSTI on Quantisnow?
Quantisnow aggregates Pluristem Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PSTI to receive live email and push alerts on every new disclosure.